Ionis Pharmaceuticals Analyst Ratings
How Is The Market Feeling About Recursion Pharmaceuticals?
CareDx Analyst Ratings
CareDx Stock Climbs 16% on Medicare Coverage Update
Cisco Posts Upbeat Earnings, Joins Tesla, Ulta Beauty, Robinhood, Dell And Other Big Stocks Moving Higher On Thursday
TJX To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Wednesday
Nurix Therapeutics Analyst Ratings
Navigating 11 Analyst Ratings For 10x Genomics
Starbucks To Rally Around 43%? Here Are 10 Top Analyst Forecasts For Tuesday
10x Genomics Analyst Ratings
Expert Ratings For Intellia Therapeutics
Lumen Tech & Upstart Are Among Top 7 Mid Cap Gainers Last Week (Aug 4-Aug 10): Are The Others In Your Portfolio?
Intellia Therapeutics Analyst Ratings
Needham Maintains Buy on Recursion Pharmaceuticals, Lowers Price Target to $16
Recursion Pharmaceuticals Analyst Ratings
AI-Powered Drug Discovery Firm Exscientia To Merge With Nvidia-Partner Recursion Pharmaceuticals
10x Genomics GAAP EPS of -$0.32 Beats by $0.16, Revenue of $153.1M Beats by $3.05M
Intellia Hereditary Angioedema Candidate Meets Phase 2 Primary Endpoint
BofA Upgrades Editas to Buy, Cites Reni-cel Progress
Cantor Fitzgerald Reiterates Neutral on CRISPR Therapeutics